Showing 683 results
-
Media Release /With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced…
-
Media Release /
-
Media Release /PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissues At 24…
-
Media Release /
-
Media Release /PROS is a spectrum of at least 13 rare conditions driven by mutations in the PIK3CA gene, typically associated with tissue overgrowth, vascular malformations, and neurological disorders New…
-
Media Release /Results from year two of the pivotal Phase III KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one1,2 In key fluid-related…
-
Media Release /
-
Media Release /Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and…
-
Media Release /
-
Media Release /
